FDA Grants Fast Track Designation to NovaBridge’s Givastomig for Metastatic Gastric Cancer
Event summary
- FDA grants Fast Track Designation to givastomig for first-line HER2-negative metastatic gastric cancer.
- Phase 1b data showed compelling efficacy and tolerability in combination with immunochemotherapy.
- Registrational Phase 3 trial expected to begin as early as Q4 2026.
- Detailed Phase 1b data to be presented at a major medical conference in H2 2026.
The big picture
NovaBridge’s Fast Track Designation for givastomig underscores the growing focus on targeted therapies for metastatic gastric cancer, a field with significant unmet medical needs. The designation accelerates development and review, potentially positioning givastomig as a key player in a competitive oncology market. The strategic partnership with ABL Bio further strengthens NovaBridge’s global reach, excluding Greater China and South Korea.
What we're watching
- Clinical Trial Execution
- The pace at which NovaBridge initiates and completes the Phase 3 trial will determine the timeline for potential approval.
- Regulatory Strategy
- Whether the FDA’s Fast Track Designation and prior confirmation of accelerated approval pathway eligibility will expedite givastomig’s market entry.
- Competitive Positioning
- How givastomig’s first-in-class and best-in-class potential will impact NovaBridge’s standing in the CLDN18.2-directed therapy space.
Related topics